Comparative Pharmacology
Head-to-head clinical analysis: NORLESTRIN 21 2 5 50 versus PORTIA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLESTRIN 21 2 5 50 versus PORTIA 21.
NORLESTRIN 21 2.5/50 vs PORTIA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate). Inhibits ovulation by suppressing gonadotropin release. Increases viscosity of cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Norethindrone: 8 hours (terminal); Ethinyl estradiol: 13 hours (terminal). Clinical context: Steady-state achieved after 3-5 days; dosing interval based on once-daily administration.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates of norethindrone and ethinyl estradiol); fecal: 30-40% via biliary elimination; <1% unchanged.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Category C
Category C
Oral Contraceptive
Oral Contraceptive